PRME · Prime Medicine, Inc.
$3.61
-0.03 (-0.82%)
At close · Aug 28
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date on which this Quarterly Report on Form 10-Q is filed. Based on the Company's cash, cash equivalents, and short-term investments as of June 30, 2026, the Company's current and forecasted level of operations, and its forecasted cash flows, the Company's ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management plans to provide for the Company's capital requirements through financing or other transactions, and selling shares under the Company's "at the market offering" program. There can be no assurance that the Company will be able to raise additional capital to fund operations with terms acceptable to the Company, or at all.”View the 10-Q filed Aug 6, 2026
Market Cap
$658.40M
Shares
181.38M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$4.63M
+55.3%
FY2025
Net Income
-$201.14M
-2.7%
FY2025
Operating Margin
-4498.06%
+2289.3pp
FY2025
Diluted EPS
-$1.35
+18.2%
FY2025
Operating Cash Flow
-$162.56M
-32.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | $4.63M | $2.98M | $0 | $0 | $0 | $5.21M | |
| $146.2M | $160.64M | $155.29M | $147.91M | $86.73M | $70.55M | $2.98M | |
| $54.39M | $52.35M | $50.16M | $43.39M | $29.82M | $13.92M | $3.16M | |
| $7.4M | $7.32M | $6.13M | $4.65M | $2.22M | $568K | $43K | |
| $200.59M | $212.98M | $205.45M | $204.79M | $116.54M | $84.47M | $6.14M | |
| -$196.52M | -$208.35M | -$202.47M | -$204.79M | -$116.54M | -$84.47M | -$932K | |
| — | -4498.06% | -6787.36% | — | — | — | -17.89% | |
| -$189.12M | -$201.03M | -$196.34M | -$200.14M | -$114.32M | -$83.91M | -$889K | |
| $4.03M | $4.15M | $3.52M | $2.81M | — | — | — | |
| $8.63M | $7.21M | $6.59M | $6.38M | -$6.23M | -$81.38M | -$611K | |
| — | $0 | $0 | -$279K | -$948K | -$486K | $1.87M | |
| -$187.89M | -$201.14M | -$195.88M | -$198.13M | -$121.82M | -$165.37M | -$3.41M | |
| — | -4342.44% | -6566.61% | — | — | — | -65.45% | |
| -$187.89M | -$201.14M | -$195.88M | -$198.13M | -$142.01M | -$184.12M | -$5.06M | |
| -$187.89M | -$201.06M | -$195.87M | -$197.76M | -$122.18M | -$165.39M | -$3.41M | |
| USD/shares | -$1.06 | -$1.35 | -$1.65 | -$2.18 | -$4.19 | -$14.19 | -$1.91 |
| USD/shares | -$1.06 | -$1.35 | -$1.65 | -$2.18 | -$4.19 | -$14.19 | -$1.91 |
| shares | — | 148.76M | 118.6M | 90.97M | 33.89M | 12.97M | 2.64M |
| shares | — | 148.76M | 118.6M | 90.97M | 33.89M | 12.97M | 2.64M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.04×
EV/EBIT
—
Peer median 11.11×
P/E (TTM)
—
Peer median 13.00×
Peer medians compare against the 309 similar-size Biotechnology companies (of 524 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $4,632,000 | $2,983,000 | $0 |
Key facts
CIK
1894562
CUSIP
74168J101
13F (30d)
159 filings
159 filers
Visit website
Investor relations